 Shelley Miyamoto
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 34 | 2023 | 671 | 3.930 |
Why?
| | Heart Defects, Congenital | 14 | 2023 | 666 | 2.840 |
Why?
| | Heart Ventricles | 15 | 2022 | 720 | 2.550 |
Why?
| | Cardiomyopathy, Dilated | 13 | 2021 | 351 | 2.490 |
Why?
| | MicroRNAs | 8 | 2023 | 604 | 1.950 |
Why?
| | Heart Failure | 16 | 2023 | 1962 | 1.940 |
Why?
| | Cardiomyopathies | 7 | 2023 | 301 | 1.710 |
Why?
| | Circulating MicroRNA | 3 | 2023 | 24 | 1.690 |
Why?
| | Myocardium | 8 | 2021 | 925 | 1.550 |
Why?
| | Hypoplastic Left Heart Syndrome | 6 | 2017 | 114 | 1.430 |
Why?
| | Milrinone | 2 | 2021 | 24 | 1.270 |
Why?
| | Myocytes, Cardiac | 7 | 2021 | 451 | 1.260 |
Why?
| | Ventricular Remodeling | 4 | 2021 | 227 | 1.250 |
Why?
| | Ventricular Function, Right | 2 | 2018 | 254 | 1.040 |
Why?
| | Cardiomyopathy, Hypertrophic | 3 | 2023 | 122 | 1.030 |
Why?
| | Heart Diseases | 5 | 2023 | 331 | 0.990 |
Why?
| | Child | 58 | 2023 | 18466 | 0.970 |
Why?
| | Graft Rejection | 8 | 2021 | 532 | 0.920 |
Why?
| | Infant | 32 | 2022 | 7966 | 0.780 |
Why?
| | Ventricular Function, Left | 5 | 2018 | 474 | 0.780 |
Why?
| | Graft Survival | 7 | 2023 | 479 | 0.760 |
Why?
| | Child, Preschool | 36 | 2021 | 9123 | 0.710 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 76 | 0.670 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 133 | 0.670 |
Why?
| | Phosphodiesterase 3 Inhibitors | 2 | 2016 | 13 | 0.650 |
Why?
| | Fever | 1 | 2020 | 281 | 0.640 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.630 |
Why?
| | Down-Regulation | 3 | 2021 | 598 | 0.620 |
Why?
| | Steroids | 2 | 2015 | 147 | 0.570 |
Why?
| | Hemodynamics | 6 | 2015 | 1024 | 0.570 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2017 | 142 | 0.550 |
Why?
| | Humans | 80 | 2023 | 115219 | 0.550 |
Why?
| | Female | 60 | 2023 | 59717 | 0.540 |
Why?
| | Male | 55 | 2023 | 55811 | 0.540 |
Why?
| | Fontan Procedure | 4 | 2023 | 160 | 0.520 |
Why?
| | Histone Deacetylases | 1 | 2017 | 196 | 0.510 |
Why?
| | Echocardiography | 6 | 2021 | 563 | 0.470 |
Why?
| | Biomarkers | 9 | 2021 | 3421 | 0.470 |
Why?
| | Case-Control Studies | 8 | 2021 | 3023 | 0.450 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 1731 | 0.430 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 481 | 0.430 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 41 | 0.410 |
Why?
| | Waiting Lists | 2 | 2013 | 222 | 0.410 |
Why?
| | Animals, Newborn | 5 | 2021 | 779 | 0.400 |
Why?
| | Recovery of Function | 2 | 2015 | 577 | 0.390 |
Why?
| | Calcium-Binding Proteins | 3 | 2021 | 205 | 0.390 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 44 | 0.380 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2017 | 24 | 0.380 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2330 | 0.380 |
Why?
| | Dexmedetomidine | 3 | 2017 | 45 | 0.370 |
Why?
| | Adolescent | 32 | 2023 | 17887 | 0.370 |
Why?
| | Phenotype | 4 | 2023 | 2814 | 0.360 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2010 | 242 | 0.350 |
Why?
| | Age Factors | 9 | 2018 | 2900 | 0.340 |
Why?
| | Prospective Studies | 11 | 2021 | 6245 | 0.330 |
Why?
| | Primary Graft Dysfunction | 1 | 2009 | 32 | 0.330 |
Why?
| | Cardiolipins | 3 | 2021 | 72 | 0.330 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 2216 | 0.320 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 49 | 0.320 |
Why?
| | Reoviridae Infections | 1 | 2009 | 52 | 0.320 |
Why?
| | Granuloma, Plasma Cell | 1 | 2008 | 12 | 0.310 |
Why?
| | Signal Transduction | 3 | 2017 | 4527 | 0.300 |
Why?
| | Retrospective Studies | 21 | 2021 | 12596 | 0.300 |
Why?
| | Myocarditis | 1 | 2009 | 94 | 0.300 |
Why?
| | Cardiac Catheterization | 4 | 2017 | 538 | 0.290 |
Why?
| | Kidney Transplantation | 2 | 2023 | 553 | 0.290 |
Why?
| | Databases, Factual | 5 | 2016 | 1136 | 0.290 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 315 | 0.280 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2022 | 38 | 0.280 |
Why?
| | Phosphorylation | 4 | 2021 | 1574 | 0.280 |
Why?
| | Calcium | 3 | 2021 | 1104 | 0.270 |
Why?
| | Immunosuppressive Agents | 4 | 2023 | 667 | 0.270 |
Why?
| | Infant, Newborn | 10 | 2021 | 5052 | 0.260 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 607 | 0.260 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 84 | 0.250 |
Why?
| | Treatment Outcome | 14 | 2021 | 9151 | 0.250 |
Why?
| | Fibrosis | 2 | 2017 | 455 | 0.240 |
Why?
| | Coronary Vessels | 2 | 2017 | 230 | 0.240 |
Why?
| | Heart-Assist Devices | 4 | 2019 | 485 | 0.230 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2023 | 9 | 0.220 |
Why?
| | Heart | 3 | 2022 | 613 | 0.220 |
Why?
| | Pulmonary Artery | 1 | 2009 | 1032 | 0.220 |
Why?
| | Sarcomeres | 1 | 2023 | 90 | 0.210 |
Why?
| | Data Accuracy | 1 | 2022 | 48 | 0.210 |
Why?
| | Cyclic AMP | 2 | 2014 | 226 | 0.210 |
Why?
| | Transcriptome | 2 | 2021 | 725 | 0.210 |
Why?
| | Fibroma | 1 | 2022 | 21 | 0.200 |
Why?
| | Heart Neoplasms | 1 | 2022 | 49 | 0.200 |
Why?
| | Barth Syndrome | 1 | 2021 | 8 | 0.200 |
Why?
| | Electron Transport Complex I | 1 | 2021 | 33 | 0.200 |
Why?
| | Longevity | 1 | 2022 | 137 | 0.190 |
Why?
| | Cardiopulmonary Bypass | 3 | 2022 | 176 | 0.190 |
Why?
| | Focal Adhesions | 1 | 2021 | 42 | 0.190 |
Why?
| | Cytokines | 1 | 2009 | 1843 | 0.190 |
Why?
| | Fetofetal Transfusion | 1 | 2021 | 21 | 0.190 |
Why?
| | Amniotic Fluid | 1 | 2021 | 64 | 0.190 |
Why?
| | Heart Rate | 3 | 2023 | 705 | 0.190 |
Why?
| | Cells, Cultured | 4 | 2019 | 3897 | 0.180 |
Why?
| | Calcium Channel Agonists | 1 | 2020 | 10 | 0.180 |
Why?
| | Probenecid | 1 | 2020 | 7 | 0.180 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 64 | 0.180 |
Why?
| | Serum | 2 | 2018 | 57 | 0.180 |
Why?
| | Isoproterenol | 2 | 2018 | 110 | 0.180 |
Why?
| | Young Adult | 12 | 2023 | 10519 | 0.180 |
Why?
| | Hypertension, Pulmonary | 3 | 2017 | 1744 | 0.180 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 119 | 0.180 |
Why?
| | ROC Curve | 3 | 2017 | 447 | 0.170 |
Why?
| | Apoptosis | 1 | 2009 | 2368 | 0.170 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2020 | 122 | 0.170 |
Why?
| | Atrial Function, Right | 1 | 2019 | 13 | 0.170 |
Why?
| | Tissue Donors | 3 | 2016 | 330 | 0.160 |
Why?
| | Troponin I | 1 | 2019 | 68 | 0.160 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 36 | 0.160 |
Why?
| | Fatty Acids | 1 | 2021 | 385 | 0.160 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 82 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 229 | 0.160 |
Why?
| | Mitochondria, Heart | 2 | 2020 | 74 | 0.160 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 36 | 0.160 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 489 | 0.160 |
Why?
| | Heart Atria | 1 | 2019 | 111 | 0.150 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2013 | 366 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2021 | 436 | 0.150 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 20 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 486 | 0.150 |
Why?
| | Time Factors | 6 | 2018 | 6157 | 0.150 |
Why?
| | Protein Kinase C beta | 1 | 2017 | 24 | 0.150 |
Why?
| | Patient Transfer | 1 | 2019 | 143 | 0.140 |
Why?
| | Animals | 10 | 2021 | 31884 | 0.140 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2017 | 15 | 0.140 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 160 | 0.140 |
Why?
| | Survival Analysis | 4 | 2021 | 1215 | 0.140 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 16 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 816 | 0.140 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 11 | 0.140 |
Why?
| | Research Design | 1 | 2022 | 933 | 0.140 |
Why?
| | Adult | 12 | 2023 | 30708 | 0.140 |
Why?
| | Electrocardiography | 3 | 2015 | 563 | 0.140 |
Why?
| | Galectin 3 | 1 | 2016 | 18 | 0.140 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 721 | 0.140 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 57 | 0.140 |
Why?
| | Specimen Handling | 1 | 2018 | 155 | 0.140 |
Why?
| | Transition to Adult Care | 1 | 2017 | 63 | 0.140 |
Why?
| | Perioperative Care | 1 | 2017 | 125 | 0.140 |
Why?
| | Vectorcardiography | 1 | 2016 | 5 | 0.140 |
Why?
| | Genetic Markers | 1 | 2017 | 323 | 0.140 |
Why?
| | Sirolimus | 1 | 2017 | 189 | 0.140 |
Why?
| | Self Care | 1 | 2019 | 352 | 0.140 |
Why?
| | Mutation | 3 | 2023 | 3350 | 0.140 |
Why?
| | Isoenzymes | 1 | 2017 | 286 | 0.140 |
Why?
| | Risk Factors | 9 | 2018 | 8658 | 0.130 |
Why?
| | Vascular Resistance | 1 | 2017 | 338 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 279 | 0.130 |
Why?
| | Plasma | 1 | 2018 | 210 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 271 | 0.130 |
Why?
| | Vasoconstriction | 1 | 2017 | 186 | 0.130 |
Why?
| | Exosomes | 1 | 2017 | 91 | 0.130 |
Why?
| | Statistics as Topic | 1 | 2016 | 298 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 499 | 0.130 |
Why?
| | Up-Regulation | 1 | 2018 | 812 | 0.130 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 248 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 81 | 0.120 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 64 | 0.120 |
Why?
| | Exercise Test | 3 | 2023 | 545 | 0.120 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 156 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 2015 | 134 | 0.120 |
Why?
| | Rats | 4 | 2021 | 4980 | 0.120 |
Why?
| | Ketamine | 1 | 2015 | 92 | 0.120 |
Why?
| | Stroke Volume | 2 | 2016 | 512 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1524 | 0.120 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 153 | 0.120 |
Why?
| | Prognosis | 4 | 2015 | 3336 | 0.120 |
Why?
| | Hypoalbuminemia | 1 | 2014 | 26 | 0.120 |
Why?
| | Organ Transplantation | 1 | 2016 | 161 | 0.110 |
Why?
| | Propensity Score | 1 | 2015 | 224 | 0.110 |
Why?
| | Patient Compliance | 1 | 2017 | 525 | 0.110 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2013 | 9 | 0.110 |
Why?
| | Growth Disorders | 1 | 2014 | 78 | 0.110 |
Why?
| | Anthracyclines | 1 | 2013 | 41 | 0.110 |
Why?
| | Coronary Angiography | 1 | 2016 | 307 | 0.110 |
Why?
| | Fetal Heart | 1 | 2013 | 37 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2016 | 231 | 0.110 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 243 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2017 | 683 | 0.110 |
Why?
| | Myosin Heavy Chains | 1 | 2014 | 178 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 42 | 0.100 |
Why?
| | Connexin 43 | 1 | 2012 | 23 | 0.100 |
Why?
| | Interleukin-1 | 1 | 2016 | 970 | 0.100 |
Why?
| | Heart Arrest | 1 | 2015 | 289 | 0.100 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 158 | 0.100 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 97 | 0.100 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 172 | 0.100 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4430 | 0.100 |
Why?
| | Altitude | 2 | 2021 | 435 | 0.100 |
Why?
| | American Heart Association | 2 | 2023 | 264 | 0.090 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2014 | 222 | 0.090 |
Why?
| | Incidence | 2 | 2015 | 2324 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 63 | 0.090 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 184 | 0.090 |
Why?
| | Lymphoproliferative Disorders | 1 | 2010 | 46 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 195 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 233 | 0.090 |
Why?
| | RNA | 1 | 2016 | 810 | 0.090 |
Why?
| | Disease Management | 1 | 2014 | 562 | 0.090 |
Why?
| | Mycoses | 1 | 2010 | 66 | 0.090 |
Why?
| | Patient Selection | 1 | 2014 | 651 | 0.090 |
Why?
| | Air Ambulances | 1 | 2010 | 34 | 0.080 |
Why?
| | Colorado | 6 | 2017 | 4099 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1317 | 0.080 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 150 | 0.080 |
Why?
| | Cohort Studies | 6 | 2015 | 4917 | 0.080 |
Why?
| | Cardiac Surgical Procedures | 2 | 2017 | 415 | 0.080 |
Why?
| | Oxygen Consumption | 2 | 2023 | 590 | 0.080 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 394 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 66 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1190 | 0.080 |
Why?
| | Travel | 1 | 2010 | 121 | 0.080 |
Why?
| | Registries | 2 | 2014 | 1765 | 0.080 |
Why?
| | Mitral Valve Stenosis | 1 | 2008 | 20 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2010 | 182 | 0.080 |
Why?
| | Angioplasty, Balloon | 1 | 2009 | 89 | 0.080 |
Why?
| | United States | 7 | 2022 | 12256 | 0.080 |
Why?
| | Reoperation | 3 | 2021 | 524 | 0.080 |
Why?
| | RNA, Transfer, Glu | 1 | 2007 | 5 | 0.070 |
Why?
| | RNA, Messenger | 3 | 2021 | 2563 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1397 | 0.070 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 77 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2021 | 926 | 0.070 |
Why?
| | Pregnancy | 2 | 2021 | 5525 | 0.070 |
Why?
| | Stem Cells | 1 | 2010 | 547 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2009 | 297 | 0.070 |
Why?
| | Myocardial Contraction | 2 | 2019 | 314 | 0.060 |
Why?
| | Stents | 1 | 2009 | 476 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1015 | 0.060 |
Why?
| | Middle Aged | 4 | 2016 | 26872 | 0.060 |
Why?
| | Pilot Projects | 2 | 2019 | 1377 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2017 | 1000 | 0.060 |
Why?
| | Risk | 2 | 2019 | 816 | 0.050 |
Why?
| | Palliative Care | 1 | 2009 | 640 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1150 | 0.050 |
Why?
| | Everolimus | 1 | 2023 | 61 | 0.050 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2552 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2023 | 81 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 746 | 0.050 |
Why?
| | Tacrolimus | 1 | 2023 | 143 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 14 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2023 | 214 | 0.050 |
Why?
| | Acyltransferases | 1 | 2021 | 46 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 52 | 0.050 |
Why?
| | Light Coagulation | 1 | 2021 | 7 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 71 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1717 | 0.050 |
Why?
| | Genotype | 2 | 2017 | 1781 | 0.050 |
Why?
| | Fetoscopy | 1 | 2021 | 28 | 0.050 |
Why?
| | Serum Response Factor | 1 | 2021 | 28 | 0.050 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 113 | 0.050 |
Why?
| | Drainage | 1 | 2021 | 151 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 605 | 0.040 |
Why?
| | Gene Expression | 2 | 2017 | 1424 | 0.040 |
Why?
| | TRPV Cation Channels | 1 | 2020 | 28 | 0.040 |
Why?
| | Postoperative Complications | 3 | 2021 | 2158 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1436 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 959 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2106 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 458 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 952 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 235 | 0.040 |
Why?
| | Resource Allocation | 1 | 2019 | 37 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 351 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2485 | 0.040 |
Why?
| | Risk Assessment | 3 | 2016 | 2981 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 590 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2017 | 1902 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 386 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 387 | 0.040 |
Why?
| | Ventricular Function | 1 | 2019 | 56 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 183 | 0.040 |
Why?
| | Flecainide | 1 | 2018 | 7 | 0.040 |
Why?
| | Treatment Failure | 2 | 2010 | 332 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 149 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 731 | 0.040 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 59 | 0.040 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 106 | 0.040 |
Why?
| | Freezing | 1 | 2018 | 85 | 0.040 |
Why?
| | Adenoidectomy | 1 | 2017 | 60 | 0.040 |
Why?
| | Cell Size | 1 | 2017 | 81 | 0.040 |
Why?
| | Kidney | 1 | 2023 | 1188 | 0.030 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 57 | 0.030 |
Why?
| | Homeostasis | 1 | 2020 | 578 | 0.030 |
Why?
| | Sampling Studies | 1 | 2016 | 94 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 298 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 3547 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 71 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 744 | 0.030 |
Why?
| | Tonsillectomy | 1 | 2017 | 72 | 0.030 |
Why?
| | Brain Death | 1 | 2016 | 32 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 750 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 304 | 0.030 |
Why?
| | Autopsy | 1 | 2016 | 85 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 151 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 171 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2645 | 0.030 |
Why?
| | Diastole | 1 | 2016 | 133 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 126 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 696 | 0.030 |
Why?
| | Systole | 1 | 2016 | 173 | 0.030 |
Why?
| | Action Potentials | 1 | 2018 | 406 | 0.030 |
Why?
| | Italy | 1 | 2015 | 92 | 0.030 |
Why?
| | Cardiac Output | 1 | 2015 | 144 | 0.030 |
Why?
| | Markov Chains | 1 | 2015 | 114 | 0.030 |
Why?
| | DNA, Complementary | 1 | 2015 | 258 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 435 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 748 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2015 | 100 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 212 | 0.030 |
Why?
| | Exons | 1 | 2015 | 301 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2017 | 182 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 779 | 0.030 |
Why?
| | Analgesics | 1 | 2015 | 157 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 77 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1323 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 699 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1231 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 958 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 827 | 0.030 |
Why?
| | Mice | 3 | 2015 | 14934 | 0.030 |
Why?
| | Exercise | 1 | 2023 | 1644 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 109 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2014 | 143 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 220 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 796 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2013 | 247 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1356 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2012 | 59 | 0.020 |
Why?
| | Pediatrics | 1 | 2019 | 986 | 0.020 |
Why?
| | Nutritional Status | 1 | 2014 | 287 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1816 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2388 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1082 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 1011 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2010 | 242 | 0.020 |
Why?
| | France | 1 | 2010 | 34 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 291 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 54 | 0.020 |
Why?
| | Body Weight | 1 | 2014 | 875 | 0.020 |
Why?
| | Shock, Cardiogenic | 1 | 2010 | 53 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1650 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 267 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 241 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 498 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2010 | 156 | 0.020 |
Why?
| | Internationality | 1 | 2010 | 144 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1860 | 0.020 |
Why?
| | Tricuspid Atresia | 1 | 2008 | 6 | 0.020 |
Why?
| | Venae Cavae | 1 | 2008 | 9 | 0.020 |
Why?
| | Vena Cava, Superior | 1 | 2008 | 21 | 0.020 |
Why?
| | Device Removal | 1 | 2009 | 127 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 546 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1050 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 449 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 140 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1155 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 2806 | 0.020 |
Why?
| | Probability | 1 | 2008 | 290 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 363 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 286 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2008 | 409 | 0.020 |
Why?
| | Aged | 2 | 2014 | 19135 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4645 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1130 | 0.020 |
Why?
| | Length of Stay | 1 | 2008 | 951 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1748 | 0.010 |
Why?
|
|
Miyamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|